Ovarian cancer cells cisplatin sensitization agents selected by mass cytometry target ABCC2 inhibition - Archive ouverte HAL
Article Dans Une Revue Future Medicinal Chemistry Année : 2018

Ovarian cancer cells cisplatin sensitization agents selected by mass cytometry target ABCC2 inhibition

Résumé

Aim: Cisplatin resistance in ovarian cancer remains a complex problem as tumors frequently develop resistance against drugs, a mechanism sometimes mediated by ATP-Binding Cassette transporters. Our goal was to find compounds restricting their inhibition capacity to the cisplatin efflux mediated by ABCC2 pump, among previously identified inhibitors, derived from the 2-indolylmethylenebenzofuranones. Methodology & results: An original method setup allows direct quantitation of platinum by employing cyTOF mass cytometry. Among tested derivatives, some led to a full platinum accumulation and efficiently resensitized cisplatin-resistant A2780 cells to cisplatin while preserving most of the calcein efflux activity. Conclusion: CyTOF is therefore a powerful and promising method to quantify cisplatin accumulation that may be used in the clinical setting to improve and personalize cancer treatment.
Fichier non déposé

Dates et versions

hal-02324758 , version 1 (22-10-2019)

Identifiants

Citer

Elisabeta Comsa, Kim-Anh Nguyen, Felicia Loghin, Ahcène Boumendjel, Marine Peuchmaur, et al.. Ovarian cancer cells cisplatin sensitization agents selected by mass cytometry target ABCC2 inhibition. Future Medicinal Chemistry, 2018, 10 (11), pp.1349-1360. ⟨10.4155/fmc-2017-0308⟩. ⟨hal-02324758⟩
57 Consultations
0 Téléchargements

Altmetric

Partager

More